Brazil's health regulator Anvisa approved the registration of five [1] new injectable semaglutide-based pens on Wednesday, July 29, 2026 [2].

This decision marks a significant shift in the availability of weight-loss and diabetes medications in Brazil. By allowing more versions of the drug to enter the market, the regulator aims to lower costs and increase patient access to treatment.

The approval follows the expiration of the patent for semaglutide in Brazil [3]. Semaglutide is the active ingredient found in popular medications such as Ozempic, which has seen high demand globally for managing type 2 diabetes and obesity.

Anvisa's move is intended to foster competition among pharmaceutical providers [3]. With five [1] new options now approved, the market is expected to move away from a single-provider dominance, a change that typically leads to more competitive pricing for consumers.

Health officials and providers said that patients currently using semaglutide should pay attention to these new options as they become available [2]. The introduction of these pens provides a broader range of therapeutic alternatives for those struggling with obesity and glycemic control.

The registration process ensures that these new injectable pens meet the safety and efficacy standards required by the Brazilian government. The agency's focus remains on expanding the reach of these treatments while maintaining strict regulatory oversight of the drug's distribution [1].

“Anvisa approved the registration of five new injectable semaglutide-based pens.”

The expiration of the semaglutide patent removes a legal monopoly, allowing generic or biosimilar versions to enter the Brazilian market. This typically results in a price drop for consumers and reduces the risk of nationwide shortages caused by reliance on a single manufacturer.